Therapeutic Focus | Drug and Biomarker Developments: The Evolution of Blockbusters?
The promise of personalized medicine has begun to be realized with several commercially successful products, notably Herceptin, Gleevec, and Rituxan that all rival conventional “blockbusters.” Higher rates of efficacy and more efficient (and therefore cost effective) trials have made products based on biomarkers increasingly intriguing and attractive to an industry chronically beset with R&D failures. Should we expect life science and pharma companies to embrace the biomarker strategy as their primary business model, or will biomarker-derived products remain a niche market? And should diagnostics be developed in tandem with pharmaceuticals or independently? A panel of experienced industry executives will focus on the real world experiences and will provide valuable insight into business and regulatory landscape surrounding biomarker technology.
Michael J. Shuster, PhD
Fenwick & West LLP
Mohr Davidow Ventures
Mitch Raponi PhD
Sr. Director, Molecular Diagnostics
Senior Director and Head of Project Management
Vice President, Research
Drug and Biomarker Developments:
The Evolution of Blockbusters?
|When:||Thursday, October 21, 2010
Registration Opens: 3:30pm
Panel Presentation: 4:00pm – 5:30pm
Networking Reception: 5:30pm – 6:30pm
|Where:||South San Francisco Conference Center,
255 South Airport Blvd.,
South San Francisco, CA
|Attire:||Business Attire Suggested|